Savior Lifetec
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more
Savior Lifetec (4167) - Net Assets
Latest net assets as of September 2025: NT$3.69 Billion TWD
Based on the latest financial reports, Savior Lifetec (4167) has net assets worth NT$3.69 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.11 Billion) and total liabilities (NT$420.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.69 Billion |
| % of Total Assets | 89.79% |
| Annual Growth Rate | 7.87% |
| 5-Year Change | 5.58% |
| 10-Year Change | 120.88% |
| Growth Volatility | 17.19 |
Savior Lifetec - Net Assets Trend (2011–2024)
This chart illustrates how Savior Lifetec's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Savior Lifetec (2011–2024)
The table below shows the annual net assets of Savior Lifetec from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.52 Billion | +4.50% |
| 2023-12-31 | NT$3.36 Billion | -0.07% |
| 2022-12-31 | NT$3.37 Billion | +1.63% |
| 2021-12-31 | NT$3.31 Billion | -0.52% |
| 2020-12-31 | NT$3.33 Billion | +50.43% |
| 2019-12-31 | NT$2.21 Billion | +19.30% |
| 2018-12-31 | NT$1.86 Billion | -14.20% |
| 2017-12-31 | NT$2.16 Billion | +2.07% |
| 2016-12-31 | NT$2.12 Billion | +33.13% |
| 2015-12-31 | NT$1.59 Billion | +23.07% |
| 2014-12-31 | NT$1.29 Billion | -7.23% |
| 2013-12-31 | NT$1.39 Billion | +9.37% |
| 2012-12-31 | NT$1.27 Billion | -2.94% |
| 2011-12-31 | NT$1.31 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Savior Lifetec's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 42683500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$182.38 Million | 5.20% |
| Other Components | NT$3.33 Billion | 94.80% |
| Total Equity | NT$3.51 Billion | 100.00% |
Savior Lifetec Competitors by Market Cap
The table below lists competitors of Savior Lifetec ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sunny Friend Environmental Technology Co Ltd
TW:8341
|
$168.01 Million |
|
Advanced Process Systems Corporation
KQ:265520
|
$168.04 Million |
|
WEYCO GRP INC. DL 1
F:WY1
|
$168.06 Million |
|
Joyvio Agriculture Development Co Ltd
SHE:300268
|
$168.07 Million |
|
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
|
$167.95 Million |
|
PT Bangun Kosambi Sukses Tbk
JK:CBDK
|
$167.95 Million |
|
Baoding Dongli Machinery Co.Ltd.
SHE:301298
|
$167.94 Million |
|
Zhejiang Taifu Pump Co. Ltd
SHE:300992
|
$167.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Savior Lifetec's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,352,742,000 to 3,508,095,000, a change of 155,353,000 (4.6%).
- Net income of 182,380,000 contributed positively to equity growth.
- Dividend payments of 27,027,000 reduced retained earnings.
- Other comprehensive income decreased equity by 40,060,000.
- Other factors increased equity by 40,060,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$182.38 Million | +5.2% |
| Dividends Paid | NT$27.03 Million | -0.77% |
| Other Comprehensive Income | NT$-40.06 Million | -1.14% |
| Other Changes | NT$40.06 Million | +1.14% |
| Total Change | NT$- | 4.63% |
Book Value vs Market Value Analysis
This analysis compares Savior Lifetec's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.08x to 1.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | NT$9.86 | NT$20.50 | x |
| 2012-12-31 | NT$8.73 | NT$20.50 | x |
| 2013-12-31 | NT$8.34 | NT$20.50 | x |
| 2014-12-31 | NT$7.19 | NT$20.50 | x |
| 2015-12-31 | NT$8.00 | NT$20.50 | x |
| 2016-12-31 | NT$8.56 | NT$20.50 | x |
| 2017-12-31 | NT$8.32 | NT$20.50 | x |
| 2018-12-31 | NT$7.13 | NT$20.50 | x |
| 2019-12-31 | NT$8.16 | NT$20.50 | x |
| 2020-12-31 | NT$9.89 | NT$20.50 | x |
| 2021-12-31 | NT$10.43 | NT$20.50 | x |
| 2022-12-31 | NT$10.57 | NT$20.50 | x |
| 2023-12-31 | NT$9.90 | NT$20.50 | x |
| 2024-12-31 | NT$11.05 | NT$20.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Savior Lifetec utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.20%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.98%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.25x
- Recent ROE (5.20%) is above the historical average (-10.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -17.86% | -29.83% | 0.34x | 1.78x | NT$-365.90 Million |
| 2012 | -35.52% | -54.05% | 0.35x | 1.87x | NT$-580.31 Million |
| 2013 | -16.40% | -22.86% | 0.36x | 1.98x | NT$-368.13 Million |
| 2014 | -27.51% | -34.92% | 0.33x | 2.42x | NT$-485.13 Million |
| 2015 | -31.02% | -44.06% | 0.35x | 2.04x | NT$-652.98 Million |
| 2016 | -9.80% | -13.56% | 0.45x | 1.62x | NT$-419.62 Million |
| 2017 | 1.03% | 1.38% | 0.41x | 1.83x | NT$-194.03 Million |
| 2018 | -19.37% | -32.55% | 0.31x | 1.90x | NT$-545.12 Million |
| 2019 | -1.99% | -3.34% | 0.33x | 1.82x | NT$-265.43 Million |
| 2020 | 7.54% | 13.73% | 0.38x | 1.45x | NT$-82.08 Million |
| 2021 | -0.14% | -0.27% | 0.38x | 1.37x | NT$-336.05 Million |
| 2022 | 0.61% | 1.63% | 0.29x | 1.32x | NT$-314.63 Million |
| 2023 | 0.90% | 2.86% | 0.27x | 1.14x | NT$-305.24 Million |
| 2024 | 5.20% | 14.98% | 0.28x | 1.25x | NT$-168.43 Million |
Industry Comparison
This section compares Savior Lifetec's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Savior Lifetec (4167) | NT$3.69 Billion | -17.86% | 0.11x | $167.97 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |